An observational study in Myelodysplastic Syndromes (MDS), sponsored by Bristol-Myers Squibb. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Bristol-Myers Squibb · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb — 4 open to participants now, 9 under way, 5 of them phase 3. Myelodysplastic Syndromes · Bristol-Myers Squibb.
Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, this one is the 6th largest by planned enrollment of the 28 observational ones that give a count, is one of 3 that started in 2026, is one of 28 observational ones, and was the 73rd registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.
Browse Myelodysplastic Syndromes studies →4 of the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Germany
Ages 18+
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
Celgene · Sites in United States, Australia, Belgium and 19 more countries
Ages 18+
By country, each count listing its studies:
Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 20 · Phase 3 12 · Phase 4 1
First in 2001; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 150 across 214 observational studies indexed under Myelodysplastic Syndromes.
Median enrollment 56 across the 46 interventional studies, 200 across the 28 observational. Of the 63 that completed or were terminated, 20 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to provide a contemporary view and offer invaluable insights into the demographic profiles, clinical characteristics, treatments, and real-world outcomes of individuals with myelodysplastic syndromes (MDS) in Asia.
The registry will include adults who were/are newly diagnosed with myelodysplastic syndromes (MDS) in Asia (Singapore, South Korea and Taiwan).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Retrospective enrolment of Myelodysplastic Syndrome (MDS) participants:
Inclusion criteria for the prospective enrolment of MDS participants:
Exclusion Criteria:
Participants diagnosed with myelodysplastic syndromes (MDS)
Drug: Prescribed treatments for myelodysplastic syndromes (MDS)
According to the product label
Participant age
Time frame: Baseline
Participant sex
Time frame: Baseline
Participant race
Time frame: Baseline
Participant weight
Time frame: Baseline
Participant height
Time frame: Baseline
Participant body mass index (BMI)
Time frame: Baseline
Participant smoking status
Time frame: Baseline
Participant drinking status
Time frame: Baseline
Family history of MDS or other hematopoietic cancers
Time frame: Baseline
Participant myelodysplastic syndromes diagnosis information
Time frame: Baseline
Participant Eastern Cooperative Oncology Group (ECOG) Performance status at diagnosis
Time frame: Baseline
Participant comorbidities at diagnosis
Time frame: Baseline
Participant Charlson comorbidity index (CCI) score at diagnosis
Time frame: Baseline
Prior clinical diagnosis of other cancers
Time frame: Baseline
Prior clinical diagnosis of hematological diseases
Time frame: Baseline
Anemia status at diagnosis
Time frame: Bseline
Thrombocytopenia status at diagnosis
Time frame: Baseline
Neutropenia status at diagnosis
Time frame: Baseline
Iron overload status at diagnosis
Time frame: Baseline
Red blood cell (RBC) transfusion dependence status at diagnosis
Time frame: Baseline
International Prognostic Scoring System (IPSS) score at diagnosis
Time frame: Baseline
Revised International Prognostic Scoring System (IPSS-R) score at diagnosis
Time frame: Baseline
Molecular International Prognostic Scoring System (IPSS-M) score at diagnosis
Time frame: Baseline
Bone marrow aspirate results
Time frame: Baseline and up to 2-years
Presence of dysplasia
Time frame: Baseline and up to 2-years
Cytogenetic test results
Time frame: Baseline and up to 2-years
Mutation test results at diagnosis
Time frame: Baseline
Complete blood count test results at diagnosis
Time frame: Baseline
Mean corpuscular volume (MCV)
Time frame: Baseline and up to 2-years
C-reactive protein (CRP)
Time frame: Baseline and up to 2-years
Serum ferritin (SF) level
Time frame: Baseline and up to 2-years
Serum erythropoietin levels
Time frame: Baseline and up to 2-years
Lactate dehydrogenase (LDH)
Time frame: Baseline and up to 2-years
Initial treatment received following diagnosis
Time frame: Baseline
Prior treatments and concomitant medications received
Time frame: Baseline
Subsequent treatments received
Time frame: Up to 2-years
Time from diagnosis to treatment initiation
Time frame: Baseline
Treatment duration
Time frame: Up to 2-years
Real-world overall survival (rwOS)
Time frame: Baseline and up to 2-years
Time to disease-risk progression (per IPSS-R)
Time frame: Baseline and up to 2-years
Time to acute myeloid leukemia (AML) progression
Time frame: Baseline and up to 2-years
Time to iron overload
Time frame: Baseline and up to 2-years
Overall response rate (ORR)
Time frame: Baseline and up to 2-years
Duration of response (DOR)
Time frame: Baseline and up to 2-years
Real-world relapse-free survival (rwRFS)
Time frame: Baseline and up to 2-years
Plan to share: No
Started Aug 2026 (actual). Primary completion is estimated for Oct 2026, 2 months after the start.
Of 102 observational studies under Myelodysplastic Syndromes, half reached primary completion within 84 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 154. This study's planned 2 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Mar 2026 → Aug 2026, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.